ArcticZymes Technologies ASA (STU:B4V)
€ 1.114 -0.002 (-0.18%) Market Cap: 56.93 Mil Enterprise Value: 37.30 Mil PE Ratio: 167.50 PB Ratio: 2.15 GF Score: 62/100

Q1 2020 Biotec Pharmacon ASA Earnings Call Transcript

Apr 23, 2020 / 06:30AM GMT
Release Date Price: €0.97 (+38.57%)
Jethro Holter
Biotec Pharmacon ASA - CEO

Okay. Welcome to the Q1 presentation. Before we kick off and go through things, just some practical things. Of course, this is a bit different to usual. So we've -- since we're all in home office and can't meet together, we're doing this by video teleconference. And so what I would kindly ask is that you ensure that you have your microphones muted. This will help to reduce background noise. And if you are sharing your video, please turn that off because it helps us have the best bandwidth to prevent dropouts during the presentation.

So today, it's myself, Jethro Holter, now the permanent CEO of Biotec Pharmacon; and we have Børge Sørvoll, our CFO, who will join us in -- late in the presentation. So for those of you who are not watching the stream live, I will tell you which slide number on, so we're going on to Slide #2, the agenda.

So in terms of the agenda today, what I'm going to do is we're going to walk you through the Q1 highlights. Then we're going to look at each of the businesses in turn, looking at ArcticZymes first, then Biotec

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot